NL-OMON41826
Completed
Not Applicable
Efficacy and safety of a new EMR device for early neoplasia in the Barrett's esophagus. - PreCap-studie
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- esophageal cancer
- Sponsor
- Academisch Medisch Centrum
- Enrollment
- 11
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Age 18\-80 years
- •2\. Subject is scheduled for esophagectomy
- •3\. Subject is willing to participate, fully understands the content of the informed consent form, and signs the informed consent form.;Phase II
- •1\. Age 18\-80 years
- •2\. Barrett esophagus with a visible abnormality and biopsy\-proven high grade dysplasia and/or early cancer
- •3\. Lesion with a maximum size of 4 cm in longitudinal length and 50% of the circumference.
- •4\. No suspicion of submucosal invasion, based on the macroscopic appearance and/or endosonography
- •5\. No signs of lymph node and/or distant metastasis on endosonography and CT\-scanning of the thorax and abdomen.
- •6\. Patient is scheduled for endoscopic resection of present BE neoplasia
- •7\. Subject is willing to participate, fully understands the content of the informed consent form, and signs the informed consent form.
Exclusion Criteria
- •1\. Subject has previously undergone endoscopic therapy in the intended treatment zone, including (but not limited to) cryospray therapy, laser treatment, photodynamic therapy, endoscopic mucosal resection, radiofrequency ablation or argon plasma coagulation.
- •2\. Presence of esophageal stenosis limiting access to the intended treatment zone.
- •3\. Scarring by other causes of the intended treatment zone.
- •4\. Subject refuses or is not able to provide written informed consent.;Phase II
- •1\. Subject has previously undergone endoscopic therapy in the intended treatment zone, including (but not limited to) cryospray therapy, laser treatment, photodynamic therapy, endoscopic mucosal resection, radiofrequency ablation or argon plasma coagulation.
- •2\. Presence of esophageal stenosis limiting access to the intended treatment zone.
- •3\. Scarring by any cause of the intended treatment zone.
- •4\. Subject refuses or is not able to provide written informed consent.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
ext Generation Automated Insulin Delivery in Children and Adults with Type 1 DiabetesType 1 diabetesMetabolic and Endocrine - DiabetesACTRN12624000907549Health New Zealand - Southern30
Not yet recruiting
Not Applicable
Evaluation of a Medtronic extended-life glucose sensor in people with diabetesType 1 diabetesMetabolic and Endocrine - DiabetesACTRN12620001161910St Vincent's Hospital Melbourne40
Not yet recruiting
Not Applicable
Efficacy and safety of a novel device (OptimosTM Dilatation Device) in endoscopic retrograde cholangiopancreatography (ERCP) for removal of biliary stonesKCT0006185Chonnam National University Hospital20
Completed
Not Applicable
Clinical evaluation of a novel device for the treatment of periodontitis by applying a photolysis of hydrogen peroxide disinfection techniquePeriodontal diseaseJPRN-UMIN000011511Tohoku University Graduate School of Dentistry25
Completed
Not Applicable
Clinical evaluation of a novel device for the treatment of periodontitis by applying a radical disinfection techniquePeriodontal diseaseJPRN-UMIN000007312Tohoku University Graduate School of Dentistry10